Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
41.10
-2.64 (-6.04%)
At close: Feb 27, 2026, 4:00 PM EST
41.05
-0.05 (-0.12%)
After-hours: Feb 27, 2026, 7:04 PM EST
Crinetics Pharmaceuticals Employees
Crinetics Pharmaceuticals had 437 employees as of December 31, 2024. The number of employees increased by 147 or 50.69% compared to the previous year.
Employees
437
Change (1Y)
147
Growth (1Y)
50.69%
Revenue / Employee
$17,611
Profits / Employee
-$1,064,799
Market Cap
4.30B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 437 | 147 | 50.69% | 437 | 0 |
| Dec 31, 2023 | 290 | 80 | 38.10% | 290 | 0 |
| Dec 31, 2022 | 210 | 67 | 46.85% | 210 | 0 |
| Dec 31, 2021 | 143 | 50 | 53.76% | 143 | 0 |
| Dec 31, 2020 | 93 | 25 | 36.76% | 93 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ACADIA Pharmaceuticals | 654 |
| Amicus Therapeutics | 511 |
| TG Therapeutics | 374 |
| Structure Therapeutics | 218 |
| Scholar Rock Holding | 128 |
| Centessa Pharmaceuticals | 114 |
| Erasca | 103 |
| NewAmsterdam Pharma Company | 100 |
CRNX News
- 2 days ago - Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 23 days ago - Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March - GlobeNewsWire
- 4 weeks ago - Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 5 weeks ago - Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - GlobeNewsWire
- 6 weeks ago - Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - GlobeNewsWire